Presentation is loading. Please wait.

Presentation is loading. Please wait.

An open-label study evaluating the efficacy and tolerability of alefacept for the treatment of scalp psoriasis  James Krell, MD, FAAD, Candi Nelson, BS,

Published byΛεφτέρις Λαιμός Modified over 5 years ago

Similar presentations

Presentation on theme: "An open-label study evaluating the efficacy and tolerability of alefacept for the treatment of scalp psoriasis  James Krell, MD, FAAD, Candi Nelson, BS,"— Presentation transcript:

1 An open-label study evaluating the efficacy and tolerability of alefacept for the treatment of scalp psoriasis  James Krell, MD, FAAD, Candi Nelson, BS, CCRC, Linda Spencer, RN, BSN, CCRC, Stephen Miller, MD, FAAD  Journal of the American Academy of Dermatology  Volume 58, Issue 4, Pages (April 2008) DOI: /j.jaad Copyright © 2008 American Academy of Dermatology, Inc. Terms and Conditions

2 Fig 1 Study design. S-PGA, Scalp Physician's Global Assessment.
Journal of the American Academy of Dermatology  , DOI: ( /j.jaad ) Copyright © 2008 American Academy of Dermatology, Inc. Terms and Conditions

3 Fig 2 Patient disposition. S-PGA, Scalp Physician's Global Assessment.
Journal of the American Academy of Dermatology  , DOI: ( /j.jaad ) Copyright © 2008 American Academy of Dermatology, Inc. Terms and Conditions

4 Fig 3 Cumulative percentage of patients who scored scalp Physician's Global Assessment (S-PGA) 0 or 1, attained 75% improvement in scalp-specific modified Psoriasis Area and Severity Index (S-mPASI 75), or rated themselves as much improved by scalp Patient's Global Assessment (S-PaGA) at 6 weeks after either treatment course. Not all patients required both courses. Journal of the American Academy of Dermatology  , DOI: ( /j.jaad ) Copyright © 2008 American Academy of Dermatology, Inc. Terms and Conditions

5 Fig 4 Condition of scalp psoriasis in patient before (A) and after (B) treatment with alefacept. Patient had scalp-specific modified Psoriasis Area and Severity Index scores of 1.5 before treatment (A) and 0.8 after treatment (B). Journal of the American Academy of Dermatology  , DOI: ( /j.jaad ) Copyright © 2008 American Academy of Dermatology, Inc. Terms and Conditions

Download ppt "An open-label study evaluating the efficacy and tolerability of alefacept for the treatment of scalp psoriasis  James Krell, MD, FAAD, Candi Nelson, BS,"

Similar presentations

The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24- week, randomized, double-blind, placebo-controlled phase 3b study  Jerry.

The effect of secukinumab on moderate-to-severe scalp psoriasis: Results of a 24- week, randomized, double-blind, placebo-controlled phase 3b study  Jerry.
Yul W. Yang, MD, PhD, David J. DiCaudo, MD 

Yul W. Yang, MD, PhD, David J. DiCaudo, MD 
Psoriasis: Latitude does make a difference

Psoriasis: Latitude does make a difference
OBSERVE-5: Observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results  Alexa B. Kimball,

OBSERVE-5: Observational postmarketing safety surveillance registry of etanercept for the treatment of psoriasis final 5-year results  Alexa B. Kimball,
Image registration of sequential transparent photographs to localize and detect new versus recurrent tumors in dermatologic and Mohs micrographic surgery 

Image registration of sequential transparent photographs to localize and detect new versus recurrent tumors in dermatologic and Mohs micrographic surgery 
Baldness reversed by chemotherapy

Baldness reversed by chemotherapy
Megan Wood, MD, Tom Raisanen, MD, Ingrid Polcari, MD 

Megan Wood, MD, Tom Raisanen, MD, Ingrid Polcari, MD 
Efficacy of simvastatin in plaque psoriasis: A pilot study

Efficacy of simvastatin in plaque psoriasis: A pilot study
Elana Putterman, BS, Leslie Castelo-Soccio, MD, PhD 

Elana Putterman, BS, Leslie Castelo-Soccio, MD, PhD 
Sarah Sung, MD, Alexa B. Kimball, MD, MPH 

Sarah Sung, MD, Alexa B. Kimball, MD, MPH 
María Jesús Suárez Valladares, MD, Manuel Ángel Rodríguez Prieto, MD 

María Jesús Suárez Valladares, MD, Manuel Ángel Rodríguez Prieto, MD 
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to.

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to.
Two randomized, double-blind, placebo-controlled studies of fluticasone propionate lotion 0.05% for the treatment of atopic dermatitis in subjects from.

Two randomized, double-blind, placebo-controlled studies of fluticasone propionate lotion 0.05% for the treatment of atopic dermatitis in subjects from.
The impact of secukinumab treatment on the prevalence of human papillomavirus in patients with psoriasis: A pilot study  Hsien-Yi Chiu, MD, Tsen-Fang.

The impact of secukinumab treatment on the prevalence of human papillomavirus in patients with psoriasis: A pilot study  Hsien-Yi Chiu, MD, Tsen-Fang.
Katherine E. Brick, BS, Robert H. Cook-Norris, MD, David A

Katherine E. Brick, BS, Robert H. Cook-Norris, MD, David A
The efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasis  Alan Menter, MD, Jennifer C. Cather, MD, Diane.

The efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasis  Alan Menter, MD, Jennifer C. Cather, MD, Diane.
Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled.

Apremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled.
Dermatology physician extenders: A new risk factor?

Dermatology physician extenders: A new risk factor?
Assessing adherence with phototherapy protocols

Assessing adherence with phototherapy protocols
Khanh P. Thieu, BS, Harley A. Haynes, MD 

Khanh P. Thieu, BS, Harley A. Haynes, MD 

Similar presentations

Ads by Google